Does Fallon Community Health Plan (FCHP) Cover Eliquis?

How Fallon Community Health Plan Handles Eliquis on Its Formulary

Fallon Community Health Plan, based in Worcester, Massachusetts, operates commercial HMO, PPO, and Medicare Advantage plans across the state. Each plan type maintains its own drug formulary, and Eliquis placement differs accordingly. On most FCHP commercial plans, Eliquis sits on a preferred brand tier (commonly Tier 3), which means a moderate copay applies but no generic substitution is forced at the pharmacy counter.

FCHP Medicare Advantage plans follow Centers for Medicare & Medicaid Services (CMS) formulary guidelines. CMS requires that Medicare Part D plans cover at least two drugs in every pharmacological class, and direct oral anticoagulants (DOACs) like Eliquis typically meet this threshold [1]. The 2025 Medicare Part D formulary reference confirms that most Medicare Advantage plans nationwide include at least one factor Xa inhibitor. FCHP's Medicare Advantage formulary has historically listed Eliquis, though tier placement can shift during annual formulary reviews each January.

Your actual cost depends on the specific benefit design. A member on an FCHP Direct Care HMO plan, for instance, may face a $47 copay for a 30-day supply of Eliquis 5 mg twice daily. A member on a different FCHP PPO product could pay $85 or more for the same prescription. The only reliable way to confirm your exact copay is to check your plan's Summary of Benefits or call FCHP member services directly.

Why Eliquis Is Widely Covered by Health Plans

Eliquis earned broad formulary inclusion because of strong clinical trial data showing it reduces stroke risk in atrial fibrillation while causing fewer major bleeds than warfarin. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, P<0.001 for noninferiority, P=0.01 for superiority) and lowered major bleeding by 31% (2.13% vs. 3.09% per year, P<0.001) [2]. That combination of better efficacy and better safety made Eliquis the most prescribed anticoagulant in the United States by 2018.

The American College of Cardiology/American Heart Association (ACC/AHA) 2023 atrial fibrillation guideline gives DOACs a Class I recommendation over warfarin for stroke prevention in eligible patients with non-valvular atrial fibrillation [3]. Dr. Fred Kusumoto, chair of the ACC/AHA writing committee, stated: "Direct oral anticoagulants should be the first-line choice for most patients with atrial fibrillation who need anticoagulation, based on consistent evidence of a favorable benefit-risk profile compared to warfarin."

Given this guideline backing, health plans that exclude Eliquis entirely risk both regulatory scrutiny and member complaints. Most commercial insurers and Medicare Advantage plans cover it, though cost-sharing varies widely.

Prior Authorization and Step Therapy Requirements at FCHP

Some FCHP plans require prior authorization before dispensing Eliquis. This is more common on Medicare Advantage and Medicaid managed care plans than on commercial HMO products. Prior authorization typically involves your prescribing physician confirming an FDA-approved indication (atrial fibrillation, DVT, PE, or post-surgical thromboprophylaxis) and documenting that the dose aligns with FDA labeling.

Step therapy is a separate barrier. Certain FCHP benefit designs require a trial of warfarin or a lower-cost anticoagulant before approving Eliquis. If your plan enforces step therapy, your doctor can request a step therapy exception by documenting a clinical reason why warfarin is inappropriate. Valid reasons include: difficulty maintaining a stable INR, dietary restrictions incompatible with warfarin, drug-drug interactions with warfarin, history of warfarin-related bleeding, or patient inability to attend regular INR monitoring appointments.

The exception process at FCHP typically takes 48 to 72 hours for a standard review. Urgent requests (for example, a patient discharged from the hospital on Eliquis after a new DVT diagnosis) can be expedited within 24 hours. If FCHP denies the exception, you have the right to appeal through FCHP's internal grievance process and, if needed, through the Massachusetts Office of Patient Protection.

What Eliquis Costs on Different FCHP Plan Types

The retail price of Eliquis without insurance runs approximately $580 to $620 for a 30-day supply of 5 mg twice daily. With FCHP coverage, your cost drops substantially, but the exact amount hinges on your plan's tier structure and cost-sharing design.

On FCHP commercial HMO plans, brand-name drugs on the preferred tier (Tier 3) commonly carry a copay between $35 and $60 per fill. Non-preferred brand placement (Tier 4) can push the copay to $75 to $95. Some newer FCHP high-deductible health plans (HDHPs) apply coinsurance rather than flat copays. In that case, you might owe 25% to 40% of the drug's negotiated price until you meet your annual deductible, then a lower coinsurance percentage after that.

For FCHP Medicare Advantage members, Part D cost-sharing follows the standard Medicare benefit phases. During the initial coverage phase, your copay for a Tier 3 drug might be $42 to $47 per month. Once you enter the coverage gap (sometimes called the "donut hole"), manufacturer discounts under the Inflation Reduction Act provisions reduce your out-of-pocket cost. Starting in 2025, the $2,000 annual out-of-pocket cap on Medicare Part D spending applies to all Medicare beneficiaries, which limits total annual Eliquis costs for FCHP Medicare Advantage members [4].

A study published in JAMA Network Open found that the median annual out-of-pocket cost for DOACs among Medicare Part D enrollees was $1 to 044 in 2020, with the top quartile paying more than $2,100 [5]. The new $2,000 cap provides meaningful relief for high-cost DOAC users.

How to Lower Your Eliquis Cost With FCHP

Several strategies can reduce what you pay, even if your FCHP plan places Eliquis on a higher tier.

Bristol-Myers Squibb / Pfizer copay card. Commercially insured patients (not Medicare, Medicaid, or Tricare) can enroll in the Eliquis manufacturer copay assistance program. Eligible patients may pay as little as $10 per month, with the manufacturer covering up to a set annual maximum. This card works at the pharmacy counter alongside your FCHP insurance.

FCHP formulary exception request. If Eliquis is on a non-preferred tier, your physician can submit a formulary exception asking FCHP to cover it at the preferred tier copay. The request must include clinical justification explaining why alternatives (such as rivaroxaban or warfarin) are not appropriate for you. FCHP is required by Massachusetts law to respond within defined timeframes.

Bristol-Myers Squibb patient assistance program. Uninsured or underinsured patients with household income below 300% of the federal poverty level may qualify for free Eliquis through the manufacturer's patient assistance foundation. This does not apply to most FCHP members but may help those who lose coverage during transitions.

90-day mail order. FCHP offers mail-order pharmacy benefits through its preferred pharmacy network. Filling a 90-day supply by mail typically costs 2.0 to 2.5 times the 30-day copay (rather than 3 times), saving you one copay per quarter. Over a year, that amounts to roughly one to two months of free medication.

Therapeutic alternatives. If cost remains prohibitive, discuss alternatives with your doctor. Rivaroxaban (Xarelto) is the other widely prescribed factor Xa inhibitor. In the ROCKET AF trial (N=14,264), rivaroxaban was noninferior to warfarin for stroke prevention in atrial fibrillation (2.1% vs. 2.4% per year, P<0.001 for noninferiority), though it did not demonstrate superiority [6]. Some FCHP plans place rivaroxaban on a lower copay tier than Eliquis. Warfarin, available as an inexpensive generic, remains an option for patients who can maintain stable INR levels with regular monitoring.

Eliquis vs. Other Anticoagulants: What FCHP Members Should Know

Choosing an anticoagulant is a clinical decision, not just a cost decision. But understanding how your FCHP plan covers each option helps frame the conversation with your doctor.

The ACC/AHA guideline recommends DOACs over warfarin for most patients with non-valvular atrial fibrillation [3]. Among DOACs, head-to-head randomized trials comparing Eliquis directly to rivaroxaban or dabigatran are limited. A large retrospective study using Medicare claims data (N=581,451) published in the Annals of Internal Medicine found that apixaban was associated with lower rates of major bleeding compared to rivaroxaban (HR 0.60 to 95% CI 0.56 to 0.64) and dabigatran (HR 0.71 to 95% CI 0.64 to 0.78), with similar stroke prevention across all three agents [7].

Dr. Gregory Lip, a leading atrial fibrillation researcher at the University of Liverpool, noted in a 2023 European Heart Journal editorial: "When tolerability, bleeding risk, and patient adherence are weighed together, apixaban offers a favorable overall profile for the majority of AF patients, though individual circumstances should always guide the choice."

For FCHP members, the practical comparison looks like this. Eliquis requires twice-daily dosing, which some patients find inconvenient. Rivaroxaban is once daily (taken with the evening meal for the AF indication). Dabigatran (Pradaxa) is twice daily and has a reversal agent (idarucizumab) approved since 2015, while Eliquis and rivaroxaban share the reversal agent andexanet alfa (Andexxa), approved by the FDA in 2018 [8]. Your FCHP plan may cover these agents at different tier levels, so verify each drug's cost before making a switch.

Understanding Your FCHP Formulary Tier System

FCHP uses a multi-tier formulary structure common among Massachusetts health plans. The typical layout includes four to six tiers.

Tier 1 covers generic drugs at the lowest copay, often $10 to $20. Tier 2 includes preferred generics or select brands at $20 to $35. Tier 3 is the preferred brand tier, where most DOACs including Eliquis land on commercial plans, with copays from $35 to $60. Tier 4 (non-preferred brand) carries higher copays of $75 to $95. Some plans add a Tier 5 for specialty medications with coinsurance of 25% to 33%.

Formulary tier assignments change annually. FCHP's Pharmacy and Therapeutics (P&T) committee reviews clinical evidence, cost-effectiveness data, and manufacturer rebate agreements each year to determine tier placement. A drug can move from Tier 3 to Tier 4 (or vice versa) between plan years without individual member notification beyond the annual formulary update mailed each fall.

To find your current plan's formulary and verify Eliquis coverage, visit the FCHP member portal online and search the drug formulary tool, or call the pharmacy benefits number printed on your member ID card. Ask specifically: "What tier is Eliquis on my plan, and does it require prior authorization or step therapy?"

When Eliquis Might Not Be Covered

Rare situations exist where FCHP may not cover Eliquis for a particular member. Off-label use (prescribing Eliquis for an indication not approved by the FDA) may result in a coverage denial. While physicians sometimes prescribe DOACs off-label for conditions like superficial vein thrombosis or cancer-associated thrombosis, FCHP may require prior authorization with supporting clinical evidence for these uses. The CARAVAGGIO trial (N=1,170) showed apixaban was noninferior to dalteparin for cancer-associated venous thromboembolism (5.6% vs. 7.9% recurrence at 6 months) with lower major bleeding (3.8% vs. 4.0%), which has expanded coverage for this indication at many insurers [9].

Dose discrepancies can also trigger denials. The FDA-approved dose for atrial fibrillation is 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for patients meeting at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. If a prescription does not match these dosing parameters, FCHP's pharmacy benefit manager may flag it for clinical review.

Members who switch FCHP plans mid-year (for example, moving from a commercial HMO to a Medicare Advantage plan during a qualifying life event) should verify that Eliquis remains on the new plan's formulary. Formularies differ between FCHP product lines, and a drug covered on one plan is not automatically covered on another.

Filing an Appeal if FCHP Denies Eliquis Coverage

If FCHP denies coverage for Eliquis, the denial letter must include the specific reason and instructions for appeal. Massachusetts General Law Chapter 176O requires health plans to provide a standard internal appeal process and, if that fails, an external review through the state's Office of Patient Protection.

For the internal appeal, your physician should submit a letter of medical necessity detailing why Eliquis is required for your clinical situation and why alternatives are not suitable. Include relevant medical records, lab results (such as renal function for dose justification), and references to clinical guidelines. The ACC/AHA atrial fibrillation guideline's Class I recommendation for DOACs over warfarin [3] is a strong supporting reference.

FCHP must respond to standard internal appeals within 30 days and urgent appeals within 72 hours under Massachusetts regulations. If the internal appeal is denied, you can file for external review within four months of the denial. The external reviewer is an independent clinical panel, not affiliated with FCHP, and their decision is binding on the health plan.

According to CMS data on Medicare Advantage appeals, approximately 75% of first-level prescription drug appeals result in at least a partial favorable decision for the member when accompanied by physician documentation [10].